{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-25-000711","form_type":"8-K","ticker":"INSM","cik":"0001104506","company_name":"INSMED Inc","filed_at":"2025-01-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:02.941266+00:00","generated_at":"2026-05-28T04:29:19.753083+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"confidence":"high","headline":"Insmed reports preliminary 2024 ARIKAYCE revenue of $363.7M, sets 2025 guidance of $405-425M","bullets":["Preliminary 2024 ARIKAYCE global net sales of $363.7M, up 19% YoY; 2025 guidance $405-425M (11-17% growth)","Brensocatib NDA for bronchiectasis submitted to FDA in Dec 2024; U.S. launch expected Q3 2025 under priority review","Phase 2 TPIP in PAH fully enrolled (102 patients); topline data now expected mid-2025","ENCORE trial for ARIKAYCE in MAC lung disease enrolled 425 patients (exceeding 400 target); topline Q1 2026","IND cleared for DMD gene therapy INS1201; first patient dosing anticipated H1 2025"],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-25-000711","json":"https://secwatch.observer/filing/0001140361-25-000711.json","markdown":"https://secwatch.observer/filing/0001140361-25-000711.md","text":"https://secwatch.observer/filing/0001140361-25-000711.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1104506/000114036125000711/0001140361-25-000711-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1104506/000114036125000711/ef20041296_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud","generated_at":"2026-05-28T04:29:19.753083+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}